Soni Medicare Reports FY26 Net Loss of Rs 2.71 Crore

HEALTHCAREBIOTECH
Whalesbook Corporate News Logo
AuthorAnanya Iyer|Published at:
Soni Medicare Reports FY26 Net Loss of Rs 2.71 Crore

Soni Medicare Limited reported a net loss of Rs 2.71 crore for FY26, widening from Rs 0.19 crore in the previous fiscal. Revenue declined to Rs 24.71 crore from Rs 29.84 crore. The management has initiated an operational reset to boost patient volumes and control costs, aiming for a break-even run-rate in the current fiscal year. Shareholders will vote on investment limits and new director appointments at the upcoming AGM.

Soni Medicare Reports Widening FY26 Losses

Net loss reached Rs 2.71 crore; annual revenue declined to Rs 24.71 crore.

Reader Takeaway: Management is executing an operational reset to improve productivity, focusing on break-even targets for current fiscal.

What just happened

Soni Medicare Limited has released its financial results for the year ended March 31, 2026, disclosing a net loss of Rs 2.71 crore compared to Rs 0.19 crore in FY25. Revenue from operations dropped to Rs 24.71 crore from Rs 29.84 crore in the previous year. The basic and diluted earnings per share (EPS) stood at -5.94, compared to -0.74 in the previous year.

Why this matters

The widened losses reflect pressure from lower patient volumes and increased costs relative to revenue. The company is now implementing an operational reset, which includes tighter performance monitoring, re-aligning consultant pay structures to productivity, and rationalizing administrative expenses. These steps are aimed at restoring profitability and stabilizing operations.

Key AGM Agenda

The 38th Annual General Meeting is set for September 29, 2026. Shareholders will vote on:

  • Increasing limits for investments and loans to an aggregate of Rs 100 crore.
  • The appointment of Mr. Lavi Kumar Mutha as an Independent Director.
  • The appointment of Mr. Namit Soni as an Executive Director.

Risks to watch

The company's turnaround success depends entirely on the effectiveness of its new management systems. Pricing pressures in government schemes and competitive challenges in patient acquisition remain notable headwinds. No dividends have been declared for the period due to the financial performance.

What to track next

Investors should monitor upcoming quarterly reports to see if the new operating system successfully improves patient volume and operating run-rates toward the targeted break-even milestone.

Disclaimer: This article is published for informational purposes only. This is not a buy sell recommendation.